论文部分内容阅读
目的:探讨围手术期持续恒温循环腹腔热灌注化疗治疗进展期腹腔恶性肿瘤的疗效及安全性。方法:选取2013年11月-2014年12月本院诊治的85例进展期腹腔恶性肿瘤患者作为研究对象,分为观察组47例和对照组38例,观察组行手术治疗、围手术期持续恒温循环腹腔热灌注化疗及术后化疗,对照组行手术治疗以及术后化疗,比较两组患者的疗效及围手术期不良反应发生情况,并进行统计学分析。结果:观察组的近期总有效率显著高于对照组,分别为82.97%和68.42%,差异具有统计学意义(P<0.05);观察组的1年生存率为77.27%,明显高于对照组的55.56%,观察组的1年复发、转移率为40.91%,明显低于对照组的66.67%,差异具有统计学意义(P<0.05);观察组的骨髓抑制及恶心呕吐比例较对照组增加,差异具有统计学意义(P<0.05);两组患者均未出现围手术期严重外科手术并发症(包括吻合口瘘、化学性腹膜炎、粘连性肠梗阻、腹腔内出血等)。结论:围手术期持续恒温循环腹腔热灌注化疗治疗进展期腹腔恶性肿瘤临床疗效显著,不良反应发生率低且安全性高。
Objective: To investigate the efficacy and safety of perioperative continuous intraperitoneal hyperthermic intraperitoneal hyperthermic perfusion chemotherapy for advanced malignant tumors of the abdominal cavity. Methods: Eighty-five patients with advanced malignancy of the peritoneal cavity diagnosed and treated in our hospital from November 2013 to December 2014 were selected and divided into observation group (n = 47) and control group (n = 38). The observation group underwent surgical treatment and the perioperative period continued The hyperthermic intraperitoneal hyperthermic perfusion chemotherapy and postoperative chemotherapy, the control group underwent surgery and postoperative chemotherapy, and the efficacy and perioperative adverse reactions in both groups were compared and statistically analyzed. Results: The total effective rate in the observation group was significantly higher than that in the control group (82.97% vs 68.42%, P <0.05). The 1-year survival rate in the observation group was 77.27%, significantly higher than that in the control group (55.56%) in the observation group. The metastasis rate was 40.91% in the observation group at one year, which was significantly lower than 66.67% in the control group (P <0.05). The proportion of bone marrow suppression and nausea and vomiting in the observation group was higher than that in the control group (P <0.05). No serious perioperative complications (including anastomotic fistula, chemical peritonitis, adhesive intestinal obstruction, intraperitoneal hemorrhage, etc.) occurred in both groups. Conclusion: Perioperative continuous intraperitoneal hyperthermic intraperitoneal hyperthermic perfusion chemotherapy in the treatment of advanced malignant tumors of the abdominal cavity has significant clinical effect, low incidence of adverse reactions and high safety.